STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes. The system was unveiled in April 2017 at the European Congress of Clinical Microbiology (ECCMID) and received a first CE-IVD marking in January 2018.

Qiagen announced today it has entered into an agreement to acquire STAT-Dx subject to closing of the transaction that is planned for the second quarter of 2018. he first two tests, which are extensive respiratory and gastrointestinal (GI) panels, are to be launched in Europe in the second half of 2018, in the U.S. in 2019.

Subject to the successful completion of defined development activities by STAT-Dx, QIAGEN has agreed to acquire all shares of STAT-Dx for approximately $147 million in cash and additional payments of up to about $44 million based on the achievement of regulatory and commercial milestones.

Caixa Capital Risc invested in 2013 in STAT-DX for the first time and continued its support during the following financing rounds. Additionally, STAT-DX took part in BioEmprendedorXXI Program, a life science entrepreneurship program of Caixa Capital Risc.

More info: